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The aim of this study was to explore the anti-tumor effect and therapeutic potential of rosmarinic acid
(RA) in the treatment of hepatocellular carcinoma (HCC). RA at 75, 150 and 300 mg/kg was given to H22
tumor-bearing mice by intragastric administration once daily for 10 consecutive days. Levels of in-
ﬂammatory and angiogenic factors, including interleukin-1b (IL-1b), interleukin-6 (IL-6), tumor necrosis
factor-a (TNF-a), vascular endothelial growth factor (VEGF), and transforming growth factor-b (TGF-b)
were measured by enzyme linked immunosorbent assays (ELISA). Protein levels of phosphorylated NF-kB
p65 and p65 were detected by western blot. mRNA level of NF-kB p65 was analyzed by qRT-PCR. The
results showed that RA could effectively suppress tumor growth with fewer toxic effects by regulating
the secretion of cytokines associated with inﬂammation and angiogenesis, and suppressing the
expression of NF-kB p65 in the xenograft microenvironment. Our ﬁndings unveil the possible anti-tumor
mechanisms of RA and support RA as a potential drug for the treatment of HCC.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of
cancer related mortality worldwide and it is still an intractable
problem though several synthetic drugs are available for HCC
clinical treatment (1,2). These synthetic drugs have low selectivity
and often cause serious adverse reaction. Therefore, the develop-
ment of novel drugs with higher efﬁciency and fewer side effects is
imperative.
Rosmarinic acid (RA; a-o-caffeoyl-3,4-dihydroxyphenyl lactic
acid) is a natural phenolic compound that exists in and thus can be
extracted from many medicinal species of Boraginaceae and Lam-
iaceae, including rosemary, mint, perilla frutescens and sarcandra
glabra (3). It has been reported that RA exerts a variety of phar-
macological activity, such as antioxidant (4), anti-angiogenic (5),
anti-inﬂammatory (6), anti-ﬁbrosis (7), and hepatoprotective (8).
These effects may be related to its phenolic hydroxyl group.rsity, 22 Shuangyong Road,
272.
ng).
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d/4.0/).Furthermore, recent studies have revealed that RA has antineo-
plastic activity in gastric carcinoma, colon carcinogenesis and leu-
kemia. Han et al. investigated the effect of RA on MKN45 human
gastric cancer cells and found that RA exerted an anti-cancer effect
via the inhibition of pro-inﬂammatory cytokines and inactivation of
the inﬂammatory pathway (9). Venkatachalam et al. analyzed the
antineoplastic activity of RA against 1,2-dimethylhydrazine
induced rat colon carcinogenesis and found that RA reversed the
decrease of antioxidant status and the elevation of CYP450 content
(10). Moon et al. reported that RA treatment sensitizes TNF-a-
induced apoptosis in human leukemia U937 cells through the
suppression of nuclear factor-kB (NF-kB) and reactive oxygen spe-
cies (ROS) (11). The above reports are several of the previous studies
on the anti-cancer effects of RA. However, its potential on HCC
therapy has rarely been explored.
The investigation of inﬂammation-associated carcinogenic
process in HCC is the most extensive. Epidemiologic study showed
that more than 90% of HCC reports are involved in inﬂammation
(12). NF-kB transcription factor, a modulator of cell growth, im-
mune responses and inﬂammation, is one of the most important
signal pathways and has been found to be constitutively active
during inﬂammation and carcinogenesis of liver (13). The hetero-
dimer p65 is a representative form of NF-kB. A key role of NF-kB innese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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(14). Activation of NF-kB p65 increases the levels of various cyto-
kines in tumor microenvironment, thereby enhancing tumor
growth (15, 16). Recent studies have also demonstrated that NF-kB
p65 is involved in angiogenesis by regulating angiogenesis factors
during HCC development (17). Therefore, NF-kB p65 is a promising
target for the treatment of HCC, in which targeting both the tumor
microenvironment and angiogenesis may be of importance. In the
present work, the H22 hepatocarcinoma xenograft tumor model
was established in mice to study the role of NF-kB p65 signaling
pathway mediated by RA in HCC and explore possible molecular
mechanisms related to inﬂammation and angiogenesis in the
xenograft microenvironment.
2. Materials and methods
2.1. H22 hepatocarcinoma xenograft tumor establishment in mice
SPF male Kunming mice weighing ranging from 18 to 22 g were
purchased from Experimental Animal Center of Guangxi Medical
University (Guangxi, China). The H22 hepatocarcinoma cell lines
were offered by Nanjing KeyGEN Technology Development. All
animal experimental procedures in this study were conducted ac-
cording to protocols approved by the institutional ethical com-
mittee of Guangxi Medical University. The feeding conditions were
as follow: temperature 25 ± 2 C, humidity 60 ± 10%, and illumi-
nation time 12 h.
After 7 days injection of H22 cells into the abdominal cavity of
Kunming mice, ascites was extracted from the tumor-bearing mice
and was diluted to the concentration of 1  107/ml with PBS. Then,
0.2 ml of the cell suspension was inoculated subcutaneously into
the right side of the axillary of each mouse. After inoculation for
24 h, the tumor-bearing mice were randomly divided into 5 groups
of 8 mice each. A group of mice without tumor inoculationwas also
included as non-tumor group. The non-tumor and model group
received the same amount of normal saline. The positive control
group received cyclophosphamide (CTX, Shanxi Powerdone Phar-
maceutics Co., Ltd., Shanxi, China) at a dosage of 20 mg/kg once
every two days via intraperitoneal injection. The low-, middle- and
high-dose RA group received rosmarinic acid diluted in normal
saline (purity > 98%, Chengdu must bio-technology Co., Ltd.,
Chengdu, China) at different dosages (75, 150 and 300 mg/kg) once
a day by intragastric administration, respectively. All animals were
euthanized after 10 days treatment. The blood samples were
collected from the eyeballs of mice. Xenograft tumors and corre-
sponding organs (liver, thymus, and spleen) were collected and
weighed.
The tumor growth inhibition rate and organ index were calcu-
lated by the formula described below:
Tumor growth inhibition rate (%) ¼ (WModel WTreated)/
WControl  100
(WModel: mean tumor weight of model mice; WTreated: mean tumor
weight of treated mice)
Organ index ¼ organ weight (mg)/body weight (g).
2.2. Analysis of serum physiochemical indexes
Serums were extracted from blood samples by centrifugation at
3000 g for 10 min. Serum levels of alanine aminotransferase (ALT),
aspartate aminotransferase (AST), blood urea nitrogen (BUN), uric
acid (UA) and creatinine (CRE) were determined by a HITACHI7100automatic biochemical analyzer (HITACHI, Japan) according to the
instructions of the manufacturer.2.3. Pathological observation
The tumor samples of each group were removed and ﬁxed with
buffered neutral 10% formalin, embedded in parafﬁn, and sliced in
5 mm thickness with a rotary microtome. The slices were stained
with hematoxylin eosin (HE) and photographed under an optical
microscope. The photographs were taken at 400 magniﬁcation.2.4. ELISA measurements of cytokines in xenografts tumor
Xenograft tumor tissues were washed and then homogenized
on icewith normal saline. Homogenates were centrifuged at 3000 g
for 10 min at 4 C and the supernatants (100 mL) were used for
analysis. Levels of interleukin-1b (IL-1b), interleukin-6 (IL-6), tumor
necrosis factor-a (TNF-a), vascular endothelial growth factor
(VEGF), and transforming growth factor-b (TGF-b) were measured
by enzyme linked immunosorbent assays (ELISA) kits (Ebioscience,
USA) in triplicate according to manufacturer's recommended
protocol.2.5. Western blot
Xenograft tumor tissues were lysed on ice in RIPA lysis buffer
(Beyotime institute of biotechnology, Jiangsu, China) for 10 min.
The lysates were centrifuged at 14,000 g for 10 min at 4 C and
supernatants were collected. The proteins were quantiﬁed with a
BCA Protein Assay Kit (BOSTER, Wuhan, China). Equal amount of
proteins (40 mg) was loaded onto 12% SDS-PAGE and transferred to
PVDF membranes (Millipore Corporation, USA). The membranes
were blocked in 5% non-fat dried milk buffered for 1 h and incu-
bated with primary antibodies against phosphorylated p65
(Ser536) (1:1000) and p65 (1:1000) (Bioworld, USA) overnight at
4 C. Then the membranes were washed and incubated with
horseradish peroxidase-conjugated secondary antibody (Cell
Signaling Technology, USA) for 2 h at room temperature. Blots were
washed three times with tris buffered saline with tween-20 (TBST)
and detected by an odyssey infrared imaging system (LI-COR, USA)
following the manufacturer's instructions. The quantiﬁcation was
normalized with the corresponding value of b-actin expression.2.6. RNA extraction and quantitative real-time PCR
Total RNA was extracted from the tumor samples by Trizol Re-
agent (Invitrogen, USA) according to the manufacturer's in-
structions. Total RNA (2 mg) was reverse transcribed to cDNA using a
RevertAid First Strand cDNA Synthesis Kit (Fermentas, USA).
Quantitative real-time PCR was performed by an Applied Bio-
systems 7300 Real-Time PCR System (Applied Biosystems, USA)
following the conditions: 95 C for 10 min, 40 cycles of 95 C
for 15 s, 60 C for 1 min. The primer sequences are listed as follows:
NF-kB p65 (forward, TGTGCGACAAGGTGCAGAAA; reverse,
TTGAGTTTCGGGTAGGCACA), and GAPDH (forward, GTGCTGAG-
TATGTCGTGGAGT; reverse, ATTGGGGGTAGGAACACGGA).2.7. Statistical analysis
All data were presented as mean ± SD. Statistical analysis was
performedwith SPSS 16.0 software. The signiﬁcance of the datawas
determined by one-way analysis of variance (ANOVA) followed by
Dunnett's t-test, and P < 0.05 was considered statistically different.
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3.1. Effects of RA on H22 xenograft tumor growth
After 10 days treatment, one of the tumor-bearing mice in
model group was dead. Mice in the treatment groups were all
survived and the survival ratio was 100%. The tumor and body
weights of mice in each group were also measured (Table 1). We
found that the positive control group and three dosage RA groups
showed marked inhibition in the growth of the H22-xenograft tu-
mor. The average tumor weight of model group was 2.28 ± 0.63 g.
Compared with the model group, the treatment of CTX and 75, 150,
and 300mg/kg RA resulted in the decreased average tumor weights
of 0.84 ± 0.39,1.39 ± 0.40,1.30 ± 0.74, and 1.18 ± 0.42 g, respectively
(P < 0.05, P < 0.01). Thus, the tumor inhibition rates of the positive
control group and RA (75, 150, and 300 mg/kg) groups were found
to be 63.15%, 39.03%, 42.98% and 48.24%, respectively. These results
suggested that the treatment of CTX and 300 mg/kg RA could
effectively inhibit the tumor growth in H22 tumor-bearing mice.
But CTX can inhibit the increase in the average body weight of
tumor-bearing mice compared with model group (P < 0.05),
whereas no signiﬁcant loss of weight was found among the RA
groups.
HE staining of the tumor tissues was observed at 400 magni-
ﬁcation to evaluate the pathological changes of each group (Fig. 1).
The results showed that tumor cells of model group were increased
in number and volume, exhibited an even distribution, signiﬁcant
morphological changes, increased nuclear volume, inﬂammation,
and vascular proliferation. Compared to the model group, the tu-
mor cells of CTX and RA groups were decreased in varying degrees.
The pathological results of high-dose RA group and CTX group
revealed that the tumor cells were broken and the percentage of
apoptotic cells was increased, which indicated that these can sup-
press growth and development of tumor cells effectively.
3.2. Toxicological effects of RA on tumor-bearing mice
In anti-cancer treatment, it could be a challenge to trigger tumor
cell death without affecting other normal organs. To explore the
toxicological impacts of RA on tumor-bearing mice, the thymus,
spleen, and liver indexes were measured. The results showed that
RA had little impacts on thymus, spleen and liver indexes (Fig. 2).
Moreover, the liver and renal function parameters including ALT,
AST, BUN, UA, and CRE were also measured. The levels of the renal
function parameters remained unchanged after the treatment of RA
whereas levels of AST were increased (Table 2). The increased levels
of ASTmay be related to the H22 hepatocarcinoma xenograft tumor
model.
3.3. Effects of RA on cytokine levels in xenograft tumor
The effects of RA on the levels of IL-1b, IL-6, TNF-a, VEGF, and
TGF-b in tumor tissues were analyzed by ELISA. As shown in Fig. 3,Table 1
Effects of RA on body weight and tumor growth in H22 tumor-bearing mice (mean ± SD
Groups Dosage (mg$kg1) Body weight (g) Incre
Pre-treatment Post-treatment
Model e 20.34 ± 1.16 33.75 ± 1.94 13.4
CTX 20 20.28 ± 0.92 28.54 ± 3.39* 8.26
RA 75 20.33 ± 1.12 32.23 ± 2.70 11.9
150 19.91 ± 1.04 30.87 ± 4.85 10.9
300 20.27 ± 1.21 30.86 ± 2.05 10.5
Model group (n ¼ 7), CTX and RA groups (n ¼ 8); *P < 0.05 vs model group, **P < 0.01 vthe treatment of CTX and 300 mg/kg RA signiﬁcantly decreased the
elevation of all these cytokines compared with those in model
group (P < 0.05, P < 0.01). For IL-1b, TNF-a and TGF-b, the middle-
dose RA group also performed obvious inhibitory effects on the
levels of IL-1b, TNF-a and TGF-b (P < 0.01).
3.4. Effect of RA on NF-kB p65 signaling in xenograft tumor
The tumor microenvironment plays a vital role in development
and progression of cancer. To assess the effects of RA on NF-kB p65
on the xenograft microenvironment in H22 tumor-bearing mice,
protein expressions of p65 and p-p65 were detected by western
blot and mRNA levels of p65 were measured by qRT-PCR in xeno-
graft tumors. Thus, the protein and mRNA expressions in these
analyses represent the expression of mouse cells inﬁltrating or
surrounding the xenografts. Phosphorylation of p65 plays an
important role in modulating NF-kB activity. Western blot
analysis showed that the CTX group and three RA groups decreased
p65 phosphorylation (Fig. 4A and B, P < 0.01). qRT-PCR results
showed that the mRNA levels of p65 were decreased after CTX and
150 mg/kg RA treatment compared with model group (Fig. 4C,
P < 0.05).
4. Discussion
Previous studies have been reported the protective effect of RA
on liver ﬁbrosis (18) and liver injury (8) due to its antioxidant and
anti-inﬂammatory properties. But its antineoplastic activities in
liver cancer are rarely reported. At present, more andmore concern
is being focused on investigating the underlying mechanisms
involved in HCC and new potential drugs in animal models. In the
present study, the H22 hepatocarcinoma xenograft tumor model
was established in mice to study anti-tumor effects and possible
molecular mechanisms of RA in HCC. The results showed that after
10 days treatment with RA, only one mouse in model group was
dead, and mice in the treatment groups were all survived. The
average tumor weights of H22 tumor-bearing mice were signiﬁ-
cantly decreased compared with model group. In addition, patho-
logical examination also demonstrated that RA could suppress
tumor cells growth and vascular proliferation. Thymus and spleen
are essential immune organs of the host animals. In this study, CTX
was used as the positive control drug. Results showed that the CTX
group can inhibit the tumor growth more effectively than RA
groups. However, it dramatically decreased the thymus and spleen
organ index, as well as the body weights of tumor-bearing mice
comparedwithmodel group, whereas RA had little inﬂuence on the
immune indexes and body weights. Moreover, RA showed little
impact on the liver index and renal function parameters. These data
suggested that RA could effectively inhibit the tumor growth with
fewer toxic effects and could be considered as a promising thera-
peutic agent in the treatment of HCC.
The functional relationship between inﬂammation and cancer
has been extensively studied. An inﬂammatory microenvironment).
ase of body weight (g) Tumor weight (g) Average inhibition rate (%)
1 ± 1.13 2.28 ± 0.63 0.00
± 1.04* 0.84 ± 0.39** 63.15
± 0.96 1.39 ± 0.40* 39.03
6 ± 1.17 1.30 ± 0.74* 42.98
9 ± 1.06 1.18 ± 0.42* 48.24
s model group.
Fig. 1. Pathological results of H22 xenograft tumor tissues after 10 days treatment with RA (HE, magniﬁcation 400). Compared with the model group, the number of tumor cells in
the CTX and RA groups was decreased in varying degrees.
Fig. 2. Effects of RA on thymus, spleen and liver indexes. Mice were treated according to the procedures described following the methods. After the last administration, thymus,
spleen and liver of the mice were collected and weighed. Organ index was measured according to the above formula. Data were presented as mean ± SD. *P < 0.05 compared with
model group.
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Table 2
Effects of RA on serum indexes of hepatic and renal functions in H22 tumor-bearing mice (mean ± SD).
Groups Dosage (mg$kg1) Serum parameters of hepatic and renal functions (U/L)
ALT AST BUN UA CRE
Non-tumor 67.40 ± 10.60 113.4 ± 13.56 8.62 ± 0.98 42.00 ± 14.71 15.60 ± 2.30
Model e 78.14 ± 15.00 474.4 ± 84.46 6.68 ± 1.28 57.25 ± 6.45 14.88 ± 2.90
CTX 20 56.00 ± 7.42* 234.4 ± 76.80** 8.37 ± 2.53 49.00 ± 4.64 15.40 ± 1.52
RA 75 76.33 ± 4.16 484.0 ± 113.5 5.13 ± 0.39 53.00 ± 5.57 14.00 ± 3.00
150 85.33 ± 17.67 447.0 ± 150.6 5.24 ± 0.62 44.33 ± 9.07 12.67 ± 1.53
300 89.00 ± 9.64 742.7 ± 99.52** 5.20 ± 0.55 52.33 ± 5.03 16.33 ± 2.31
Model group (n ¼ 7), CTX and RA groups (n ¼ 8); *P < 0.05 vs model group, **P < 0.01 vs model group.
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opment (19). However, until now, it is still a signiﬁcant challenge
that how inﬂammation promotes tumor growth and how inﬂam-
mation interacts with tumorigenesis. Even so, one fact is that
inﬂammation does inﬂuence every step of tumor development,
including tumor initiation, angiogenesis, invasion and metastasisFig. 3. Effects of RA on cytokine levels. Xenograft tumor tissues were collected after RA trea
ELISA. Data were presented as mean ± SD. *P < 0.05 compared with model group, **P < 0.0(20). During the initial stage of tumor progress, the inﬂammatory
environment can promote mutated cells proliferation (21).
Furthermore, tumor promotion triggered by inﬂammation might
occur early or late during tumorigenesis through overproduction of
pro-inﬂammatory cytokines secreted by immune or inﬂammatory
cells (22,23).tment. Levels of IL-1b, IL-6, TNF-a, VEGF, and TGF-b in tumor tissues were measured by
1 compared with model group.
Fig. 4. Effects of RA on NF-kB p65 signaling in H22 xenograft tumor tissues. (A) At the end of RA treatment, tumor lysates were prepared and quantiﬁed. Protein expressions of
p-p65 and p65 were detected by western blot. Panels 1e5 represent protein expression in model group, CTX group, and low-, middle- and high-dose RA group. (B) Densitometric
values of phosphorylated p65 were normalized to those of total p65. b-actin was used as a loading control. (C) Total RNA was extracted from xenograft tumor tissues. mRNA level of
p65 was measured by qRT-PCR. GAPDH was used as a loading control. Data were presented as mean ± SD. *P < 0.05 compared with model group, **P < 0.01 compared with model
group.
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and tumorigenesis. Phosphorylation of p65 is an important mech-
anism modulating NF-kB activity. Many stimuli can induce NF-kB
activation, including the overproduction of many cytokines.
Constitutive NF-kB activation can lead to increased levels of certain
pro-inﬂammatory cytokines, such as IL-1b, IL-6, and TNF-a. These
pro-inﬂammatory factors are powerful cytokines in NF-kB activa-
tion (24). Therefore, it is generally believed that NF-kB and
inﬂammation form a positive feedback loop (19). In this study, we
found that RA can not only decrease the overproduction of IL-1b, IL-
6, and TNF-a but also suppress the expressions of p65 and p-p65
compared with model group in the xenograft microenvironment.
These data suggested that RA has an important effect on the
expression of NF-kB p65 and the overproduction of cytokines in the
tumor microenvironment. Moreover, qRT-PCR result showed that
the mRNA level of NF-kB p65 was also decreased after RA treat-
ment, suggesting that RA can decline the transcription and trans-
lation of p65 in H22 tumor-bearing mice.
HCC is considered as a vascular-dependentmalignant tumor and
angiogenesis is related to the tumor growth and metastasis (25).
Recent studies revealed that NF-kB p65 is also involved in angio-
genesis by regulating key angiogenesis factors such as VEGF, TGF-b,
IL-6, and TNF-a (26,27). VEGF, as a pro-angiogenic factor, is a major
regulator of angiogenesis in tumor progression and the expression
of VEGF is triggered by growth factors, oncogenes and hypoxia (28).
TGF-b is another important factor in adjusting neovascularization
and act as a tumor promoter in advanced cancer. Previous studies
have showed that TGF-b is over-expressed in HCC and NF-kB is
closely related to TGF-b1 expression (29). Additionally, IL-6 and
TNF-a, known as inﬂammatory cytokines, are also well-recognized
pro-angiogenic factors which can accelerate angiogenesis and
vascular remodeling (30,31). Results of the current study showed
that RA can suppress the secretion of VEGF, TGF-b, IL-6, and TNF-a,
suggesting that RA exerts anti-tumor effects through inhibition of
angiogenic factors. The underlying mechanisms may be, at least
partly, via inhibition of NF-kB p65.
In conclusion, these studies demonstrated that RA could effec-
tively suppress the tumor growth in H22-xenografts model with
fewer toxic effects. The mechanisms involved in the anti-tumor
effect of RA on HCC were associated with inhibition of inﬂamma-
tory cytokines and angiogenic factors, as well as suppression of
NF-kB p65 in the xenograft microenvironment. The tumor micro-
environment might be a key target for the treatment of liver cancer.
These results may provide new insight into the anti-tumor mech-
anisms of RA in HCC. Based on our data, we believe that RAmay be a
potential medicine for drug development against HCC althoughmore studies are still needed to explore the underlying
mechanisms.
Conﬂict of interest
The authors declare that they have no conﬂict of interests.
Acknowledgments
This study was supported by grants from the National Natural
Science Foundation of China (81260511).
References
(1) Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer.
2010;127(12):2893e2917.
(2) Chen WQ, Liu Y, Li M, Mao JW, Zhang LR, Huang RB, et al. Anti-tumor effect of
a-pinene on human hepatoma cell lines through inducing G2/M cell cycle
arrest. J Pharmacol Sci. 2015;127:332e338.
(3) Osakabe N, Yasuda A, Natsume M, Yoshikawa T. Rosmarinic acid inhibits
epidermal inﬂammatory responses: anticarcinogenic effect of Perilla fru-
tescens extract in the murine two-stage skin model. Carcinogenesis.
2004;25(4):549e557.
(4) Yang SY, Hong CO, Lee GP, Kim CT, Lee KW. The hepatoprotection of caffeic
acid and rosmarinic acid, major compounds of Perilla frutescens, against t-
BHP-induced oxidative liver damage. Food Chem Toxicol. 2013;55:92e99.
(5) Huang SS, Zheng RL. Rosmarinic acid inhibits angiogenesis and its mechanism
of action in vitro. Cancer Lett. 2006;239(2):271e280.
(6) Chu X, Ci X, He J, Jiang L, Wei M, Cao Q, et al. Effects of a natural prolyl oli-
gopeptidase inhibitor, rosmarinic acid, on lipopolysaccharide-induced acute
lung injury in mice. Molecules. 2012;17(3):3586e3598.
(7) Li GS, Jiang WL, Tian JW, Qu GW, Zhu HB, Fu FH. In vitro and in vivo anti-
ﬁbrotic effects of rosmarinic acid on experimental liver ﬁbrosis. Phytomedi-
cine. 2010;17(3e4):282e288.
(8) Domitrovic R, Skoda M, Vasiljev Marchesi V, Cvijanovic O, Pernjak Pugel E,
Stefan MB. Rosmarinic acid ameliorates acute liver damage and ﬁbrogenesis in
carbon tetrachloride-intoxicated mice. Food Chem Toxicol. 2013;51:370e378.
(9) Han S, Yang S, Cai Z, Pan D, Li Z, Huang Z, et al. Anti-Warburg effect of ros-
marinic acid via miR-155 in gastric cancer cells. Drug Des Devel Ther. 2015;9:
2695e2703.
(10) Venkatachalam K, Gunasekaran S, Jesudoss VA, Namasivayam N. The effect of
rosmarinic acid on 1,2-dimethylhydrazine induced colon carcinogenesis. Exp
Toxicol Pathol. 2013;65(4):409e418.
(11) Moon DO, Kim MO, Lee JD, Choi YH, Kim GY. Rosmarinic acid sensitizes cell
death through suppression of TNF-alpha-induced NF-kappaB activation and
ROS generation in human leukemia U937 cells. Cancer Lett. 2010;288(2):
183e191.
(12) El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and mo-
lecular carcinogenesis. Gastroenterology. 2007;132(7):2557e2576.
(13) He G, Karin M. NF-kappaB and STAT3 e key players in liver inﬂammation and
cancer. Cell Res. 2011;21(1):159e168.
(14) Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and
liver degeneration in mice lacking the RelA component of NF-kB. Nature.
1995;376:167e170.
W. Cao et al. / Journal of Pharmacological Sciences 132 (2016) 131e137 137(15) Grivennikov SI, Greten FR, Karin M. Immunity, inﬂammation, and cancer. Cell.
2010;140(6):883e899.
(16) Kolberg M, Pedersen S, Bastani NE, Carlsen H, Blomhoff R, Paur I. Tomato paste
alters NF-kappaB and cancer-related mRNA expression in prostate cancer
cells, xenografts, and xenograft microenvironment. Nutr Cancer. 2015;67(2):
305e315.
(17) Yang FF, Li JN, Zhu JH, Wang D, Chen SS, Bai XY. Hydroxysafﬂor yellow A
inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and
NF-kB signaling pathway in H22 tumor-bearing mice. Eur J Pharmacol.
2015;754:105e114.
(18) Yang MD, Chiang YM, Higashiyama R, Asahina K, Mann DA, Mann J, et al.
Rosmarinic acid and baicalin epigenetically derepress peroxisomal
proliferator-activated receptor gamma in hepatic stellate cells for their anti-
ﬁbrotic effect. Hepatology. 2012;55(4):1271e1281.
(19) Fan Y, Mao R, Yang J. NF-kappaB and STAT3 signaling pathways collabora-
tively link inﬂammation to cancer. Protein Cell. 2013;4(3):176e185.
(20) Galun E. Liver inﬂammation and cancer: the role of tissue microenvironment
in generating the tumor-promoting niche (TPN) in the development of he-
patocellular carcinoma. Hepatology. 2016;63(2):354e356.
(21) Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their micro-
environment. Trends Genet. 2009;25(1):30e38.
(22) Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role
of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7(1):41e51.
(23) Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collabo-
ration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21(1):11e19.(24) Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic
inﬂammation and cytokines in the tumor microenvironment. J Immunol Res.
2014;2014, 149185.
(25) Carbajo-Pescador S, Ordonez R, Benet M, Jover R, Garcia-Palomo A, Mauriz JL,
et al. Inhibition of VEGF expression through blockade of Hif1alpha and STAT3
signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver
cancer cells. Br J Cancer. 2013;109(1):83e91.
(26) Schmidt D, Textor B, Pein OT, Licht AH, Andrecht S, Sator-Schmitt M, et al.
Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor
angiogenesis. EMBO J. 2007;26(3):710e719.
(27) Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in ho-
meostasis and cancer. Nat Rev Cancer. 2003;3(11):807e821.
(28) Zhang L, Wang JN, Tang JM, Kong X, Yang JY, Zheng F, et al. VEGF is essential
for the growth and migration of human hepatocellular carcinoma cells. Mol
Bio Rep. 2012;39(5):5085e5093.
(29) Ji GZ, Wang XH, Miao L, Liu Z, Zhang P, Zhang FM, et al. Role of transforming
growth factor-beta1-smad signal transduction pathway in patients
with hepatocellular carcinoma. World J Gastroenterol. 2006;12(4):
644e648.
(30) Baluk P, Yao LC, Feng J, Romano T, Jung SS, Schreiter JL, et al. TNF-alpha drives
remodeling of blood vessels and lymphatics in sustained airway inﬂammation
in mice. J Clin Invest. 2009;119(10):2954e2964.
(31) Huang SP, Wu MS, Shun CT, Wang HP, Lin MT, Kuo ML, et al. Interleukin-6
increases vascular endothelial growth factor and angiogenesis in gastric car-
cinoma. J Biomed Sci. 2004;11(4):517e527.
